EGRX Articles, Eagle Pharmaceuticals Inc. - From 12/15/23

LOS ANGELES, Dec. 15, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on ...

If you suffered losses exceeding $100,000 investing in Eagle Pharmaceuticals stock or options between August 8, 2023 and November 28, 2023 and wou...

SAN FRANCISCO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investors who suffered substantia...

ATLANTA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC informs investors that a shareholder class action lawsuit has been filed aga...

SAN DIEGO, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and...

SAN FRANCISCO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investors who suffered substantia...

NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchas...

-- BARHEMSYS® (amisulpride) Injection is the first and only antiemetic approved by the U.S. Food and Drug Administration ("FDA") for rescue t...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Dec. 05, 2023 (GLOBE NEWSWIRE) -- The Por...

SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investors who suffered substantia...